These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35333495)

  • 1. Patterns of Enrollment in Cancer Treatment Trials During the COVID-19 Pandemic at National Cancer Institute-Designated Cancer Centers.
    Prindiville SA; Sarosy GA; Loose D; Ciolino H; Doroshow JH
    Cancer J; 2022 Mar-Apr 01; 28(2):111-117. PubMed ID: 35333495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of the COVID-19 Pandemic on Tobacco Treatment Program Implementation at National Cancer Institute-Designated Cancer Centers.
    Hohl SD; Shoenbill KA; Taylor KL; Minion M; Bates-Pappas GE; Hayes RB; Nolan MB; Simmons VN; Steinberg MB; Park ER; Ashing K; Beneventi D; Sanderson Cox L; Goldstein AO; King A; Kotsen C; Presant CA; Sherman SE; Sheffer CE; Warren GW; Adsit RT; Bird JE; D'Angelo H; Fiore MC; Van Thanh Nguyen C; Pauk D; Rolland B; Rigotti NA
    Nicotine Tob Res; 2023 Jan; 25(2):345-349. PubMed ID: 35778237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute: Cancer Research and Care.
    Karzai F; Dahut WL
    Cancer J; 2022 Mar-Apr 01; 28(2):118-120. PubMed ID: 35333496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic Cancer Clinical Treatment Trials Accrual: A Closer Look at Participation Rates.
    Guerra CE; Kelly S; Redlinger C; Hernández P; Glanz K
    Am J Clin Oncol; 2021 Jun; 44(6):227-231. PubMed ID: 33710138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs.
    Samimi G; House M; Benante K; Bengtson L; Budd T; Dermody B; DeShong K; Dyer V; Kimler BF; Sahasrabuddhe VV; Siminski S; Ford LG; Vilar E; Szabo E
    Cancer Prev Res (Phila); 2022 May; 15(5):279-284. PubMed ID: 35502553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era.
    Roth ME; Unger JM; O'Mara AM; Lewis MA; Budd T; Johnson RH; Pollock BH; Blanke C; Freyer DR
    Cancer Med; 2020 Mar; 9(6):2146-2152. PubMed ID: 32009305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National Estimates of the Participation of Patients With Cancer in Clinical Research Studies Based on Commission on Cancer Accreditation Data.
    Unger JM; Shulman LN; Facktor MA; Nelson H; Fleury ME
    J Clin Oncol; 2024 Jun; 42(18):2139-2148. PubMed ID: 38564681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Masking Policies at National Cancer Institute-Designated Cancer Centers During Winter 2023 to 2024 COVID-19 Surge.
    Hoerger M; Rivera D; Mossman B; Sherard B; Peyser T; Alcorn TM
    JAMA Netw Open; 2024 Jul; 7(7):e2424999. PubMed ID: 39083276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Maryland cancer patient participation in national cancer institute-supported cancer treatment clinical trials.
    Baquet CR; Ellison GL; Mishra SI
    J Clin Oncol; 2008 Jul; 26(20):3380-6. PubMed ID: 18612153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five National Cancer Institute-designated cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: a current view and opportunities for improvement.
    Hawk ET; Habermann EB; Ford JG; Wenzel JA; Brahmer JR; Chen MS; Jones LA; Hurd TC; Rogers LM; Nguyen LH; Ahluwalia JS; Fouad M; Vickers SM
    Cancer; 2014 Apr; 120 Suppl 7(0 7):1113-21. PubMed ID: 24643649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.
    Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H
    J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organizational designs for achieving high treatment trial enrollment: a fuzzy-set analysis of the community clinical oncology program.
    Weiner BJ; Jacobs SR; Minasian LM; Good MJ
    J Oncol Pract; 2012 Sep; 8(5):287-91. PubMed ID: 23277765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of National Cancer Institute-Sponsored Clinical Trial Enrollment in Black Adolescents and Young Adults.
    Roth M; Beauchemin M; Kahn JM; Bleyer A
    Cancer Med; 2021 Nov; 10(21):7620-7628. PubMed ID: 34592782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with biomedical research participation within community-based samples across 3 National Cancer Institute-designated cancer centers.
    Barrett NJ; Rodriguez EM; Iachan R; Hyslop T; Ingraham KL; Le GM; Martin K; Haring RC; Rivadeneira NA; Erwin DO; Fish LJ; Middleton D; Hiatt RA; Patierno SR; Sarkar U; Gage-Bouchard EA
    Cancer; 2020 Mar; 126(5):1077-1089. PubMed ID: 31909824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the Coronavirus Disease 2019 (COVID-19) Outbreak With Enrollment in Cancer Clinical Trials.
    Unger JM; Blanke CD; LeBlanc M; Hershman DL
    JAMA Netw Open; 2020 Jun; 3(6):e2010651. PubMed ID: 32478845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic.
    Unger JM; Xiao H; LeBlanc M; Hershman DL; Blanke CD
    JAMA Netw Open; 2021 Jul; 4(7):e2118433. PubMed ID: 34323986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Trial Enrollment, Ineligibility, and Reasons for Decline in Older vs Younger Patients With Cancer in the National Cancer Institute Community Oncology Research Program.
    Sedrak MS; Ji J; Tiwari A; Mohile SG; Dale W; Le-Rademacher JG
    JAMA Netw Open; 2022 Oct; 5(10):e2235714. PubMed ID: 36215074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality.
    Unger JM; Stires H; Levit LA; Stewart M; McKelvey BA; Canin B; Dressler E; Flaherty K; Fredette P; Jones L; McCann P; Miller T; Onitilo AA; Palmieri F; Patel T; Paul R; Smith GL; Bruinooge SS; Garrett-Mayer E; Lei XJ; Alva A; Schenkel C
    JCO Oncol Pract; 2023 Oct; 19(10):907-916. PubMed ID: 37643386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities.
    Stewart JH; Bertoni AG; Staten JL; Levine EA; Gross CP
    Ann Surg Oncol; 2007 Dec; 14(12):3328-34. PubMed ID: 17682824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A primer for cancer research programs on defining and evaluating the catchment area and evaluating minority clinical trials recruitment.
    Nguyen LH; Cook ED
    Adv Cancer Res; 2020; 146():219-226. PubMed ID: 32241390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.